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Translational Relevance       36 
Basal cell carcinoma (BCC) is the most common malignancy in humans.  Despite the presence of 37 
cancer testis antigens, BCCs are tumors that escape from adaptive immune surveillance. Since Hh 38 
pathway inhibitors are used in the clinic to treat patients with advanced or metastatic BCC, we 39 
investigated immune alterations during this systemic therapy. In this report, we show that Hh 40 
pathway inhibitor treatment reduces tumor burden and is accompanied by a recruitment of 41 
cytotoxic T cells into the tumor and reduction in the frequency of ciliated cells, which appear to be 42 
required for Hh inhibitor efficacy. We propose that these immune responses are crucial for long-43 
term tumor control and hypothesize that a combination of Hh inhibitors with immune modifiers 44 
might be therapeutically beneficial. 45 
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Abstract   47 
Purpose:   48 
Basal cell carcinomas (BCC) are tumors ignored by immune surveillance. Activated Hedgehog 49 
(Hh) signaling within primary cilia is a key driver in the pathogenesis of BCCs. We examined 50 
immune alterations during treatment with systemic Hh inhibitors. 51 
 52 
Experimental Design:  53 
We investigated biopsies from BCC patients before (23 patients) and after 4 weeks treatment (5 54 
patients) with Hh signaling inhibitor. Ber-Ep4, BCL-2, Ki-67, CD4, CD8, MHC Class I, HLA-55 
DR-Class II, and SOX9 were analyzed by immunohistochemistry. Primary cilia were analyzed by 56 
double immunofluorescence of acetylated tubulin and SOX9. Differential gene expression for 84 57 
cytokines and chemokines were analyzed in 3 patients.  58 
Results:                                                                                                                                                                59 
After 4 weeks of treatment, we found reduction of Ki-67, SOX9, Ber-EP4, and BCL-2 expression 60 
in tumors associated with morphological signs of squamous differentiation. In addition, the 61 
number of cilia-positive BCC cells was significantly decreased. An up-regulation of MHC I 62 
expression on the cell membranes of residual tumor cells and an influx of CD4+, HLA-DR-Class 63 
II+ and CD8+ cells with invasion into the tumor cell nests was found. Finally, qPCR arrays showed 64 
the differential expression of genes involved in modulating immune responses.               65 
Conclusions:                       66 
We show that Hh pathway inhibitor-induced tumor regression is accompanied by a dynamic 67 
change of the microenvironment with a disruption of immune privilege involving an influx of 68 
cytotoxic T cells, activation of the adaptive immune functions and a profound alteration of the 69 
local chemokine/cytokine network.  70 
 71 
 72 
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Introduction 74 
Advanced basal cell carcinomas (BCCs) are a small subset of basal cell carcinomas that cause 75 
significant morbidity and remain a therapeutic challenge due to their local invasiveness and 76 
proximity to vital structures(1). Despite the presence of cancer testis and other tumor antigens, 77 
BCCs escape from immune surveillance by the down-regulation of HLA class I expression (2). 78 
Recently, targeted therapy based on knowledge of BCC pathogenesis has become available either 79 
commercially or in the context of human clinical trials. These orally available drugs such as 80 
vismodegib and sonidegib inhibit the Hedgehog (Hh) signaling pathway, and have improved the 81 
therapeutic repertoire (3-6).  82 
   The Hh pathway plays a crucial role in patterning and organogenesis during early development, 83 
and is largely inactive in the adult, except for its function in tissue repair and maintenance (7). The 84 
central components of the Hh pathway consist of three secreted ligands (Sonic Hh, Indian Hh, and 85 
Desert Hh), a negative regulatory receptor (Patched (PTCH)), a positive regulatory receptor 86 
(Smoothened (SMO), and glioma-associated oncogene (GLI) transcription factors (GLI1, GLI2, 87 
and GLI3) (7, 8). Primary cilia are involved in a number of signaling cascades including the 88 
hedgehog pathway (9). The primary cilium is a microtubule-based organelle that protrudes from 89 
the plasma membrane and acts as a sensor for extracellular signals. Hh signaling requires primary 90 
cilia. PTCH is located at the primary cilium in the absence of Hh, upon Hh binding, PTCH moves 91 
out of the cilium and SMO moves in and activates the GLI transcription factors (10, 11). In 92 
addition, a recent study showed that ciliary ablation strongly inhibited activated SMO induced 93 
BCC-like tumors(12). 94 
   Vismodegib and sonidegib inhibit SMO and achieve significant tumor regressions including 95 
complete response in locally advanced and metastatic BCCs (3-6). Hh pathway activation was 96 
linked to BCC after the initial discovery of germline loss-of-function mutations in PTCH in 97 
patients with nevoid BCC syndromes (13). Most BCCs have mutations in the Hh signaling 98 
pathway that inactivate PTCH1 (loss-of-function mutation) (8, 13) or, less commonly, 99 
constitutively activate SMO (gain-of-function mutation) (14). These mutations cause active Hh 100 
pathway signaling, which in BCCs support proliferation of the neoplasia (3). 101 
   In this study, we demonstrate that inhibition of the Hh pathway results in up-regulated MHC 102 
class I expression on BCCs and attracts MHC class II+, CD4+, and CD8+ T cells into the tumor cell 103 
nests. The in situ cytokine and chemokine networks are altered to an immune-supportive network 104 
and cilia on BCCs were decreased during the treatment of Hh pathway inhibitors. This suggests 105 
that Hh pathway inhibitors promote adaptive immune reactions in BCCs. 106 
 107 
Materials and methods 108 
Patients and treatments 109 
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We investigated biopsies of 23 BCC patients treated with vismodegib (n=22) or sonidegib (n=1). 110 
Biopsies were collected after informed consent (EK number 647) was given. Patients were treated 111 
with vismodegib (150mg daily) in the STEVIE study (a single-arm, open-label, phase II, 112 
multicenter study to assess the safety of vismodegib in patients with locally advanced or 113 
metastatic BCC) or with sonedigib (200 or 800mg daily) in the BOLT study (a phase II study of 114 
efficacy and safety in patients with locally advanced or metastatic BCC) (15).  115 
The overall response rate in those patients with measurable disease was according to Response 116 
Evaluation Criteria in Solid Tumors, Version 1.1 [RECIST, v1.1]. Evaluation of target lesions was 117 
performed as below. Complete Response: disappearance of all target lesions. Any pathological 118 
lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial 119 
Response: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the 120 
baseline sum diameters. 121 
Punch biopsies (3- 6mm) were taken before (23 samples) treatment initiation and after 4 weeks (5 122 
samples, detailed information on the patients: Table 1)) of treatment. Punch biopsies were outside 123 
the initial biopsy areas.  124 
 125 
Immunohistochemistry 126 
All tissues used for immunohistochemistry were fixed in 4% paraformaldehyde and embedded in 127 
paraffin. Sections were deparaffinized in xylene and rehydrated. Epitope retrieval was performed 128 
in antibody specific buffers. The following antibodies were used: Ber-Ep4, Bcl-2, Ki-67, CD8 129 
(DAKO, Carpinteria, CA), CD4, HLA-DR-class II (Novocastra, Newcastle, UK),  MHC class I 130 
(RDI Research Diagnostics, Flanders, NJ), CD68 (DAKO), Foxp3 (Abcam, Cambridge, UK), and 131 
Sox9 (Millipore, MA). Staining was performed using kits supplied by Ventana (Ventana , AZ) or 132 
Dako REAL Detection System (kit 5005) (Carpinteria, CA). Antigen-specific antibodies were 133 
applied and visualized with either the iVIEW DAB detection kit (Ventana) or the ChemMate 134 
detection kit (Dako). Slides were counterstained with haematoxylin and eosin (HE). The figures 135 
show representative paired pre- and post-treatment samples. 136 
 137 
Immunofluorescence  138 
Sections were deparaffinized with xylene and rehydrated with 70% EtOH. Antigen retrieval was 139 
performed at 110°C in a pressure cooker for 5 minutes in citrate buffer. Blocking was performed 140 
for 30 minutes at room temperature in blocking solution (10% Goat Serum, 0.3%Tween). 141 
Incubation with primary antibodies: acetylated Tubulin (T6793, Sigma) 1:1000 dilution and Sox9 142 
(sc-20095, Santa Cruz) 1:50 dilution. Incubation with secondary antibody: Alexa-488 goat anti-143 
mouse (Life Technologies) 1:1000 dilution and Alex-568 goat anti-rabbit (Life Technologies) 144 
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1:100 dilution. Incubation with DAPI (500ng/ml). The results showed representative paired pre- 145 
and post-treatment samples. 146 
 147 
RT-PCR 148 
Total RNA was extracted from a punch of frozen tumor material using TRIzol (Invitrogen) 149 
according to manufacturer’s instructions. cDNA was made from RT2 HT First Strand Kit (330441, 150 
Qiagen, Germany) according to manufacturer’s instructions. Genes were evaluated with the 151 
Human cytokine & chemokine PCR array (PAHS-150ZA, Qiagen, Germany) with the Viia7 152 
system from Applied Biosystems (Carlsbad, CA).  Fold change and p values were calculated by 153 
RT2 Profiler PCR Array Analysis(Qiagen). Genes were normalized to the three housekeeping 154 
genes on the array.  155 
 156 
Image analysis and quantification 157 
Images of the stained paraffin sections were acquired with Scanscope Image (Image Scope, 158 
Aperio Technologies, CA). Quantification of CD4, CD8, HLA-DR-class II, CD68, Foxp3+ cells in 159 
intratumoral and peritumoral regions was done by counting cells in high-power fields (HPF) of 160 
×40 magnification. For each section, 4 ×40 HPF representative areas per sample were counted.  161 
Immunoreactivity of Ki67 (nuclear), Sox9 (nuclear), BerEP (cytoplasm), Bcl2 (cytoplasm), and 162 
MHC class I expression (membrane of tumor cells) on tumor cells was quantified by investigation 163 
of 4 ×40 HPF representative areas per sample and evaluated as grade 1 (< 10% of cells), grade 2 164 
(10- 30% of cells) and grade 3 (>30% of cells). The number of cilia positive cells in each section 165 
was determined by counting cells in high-power fields (HPF) of ×100 magnification. The 166 
nucleated cells are counted in all experiments. A point on the immunological figures represents 167 
each single counted field. 168 
 169 
Statistical analysis   170 
Data of immunological studies and RT-PCR are presented as the means ± standard deviation (SD). 171 
RT-PCR data include data of three independent experiments. P-values were calculated with a 172 
parametric Student’s t-test. * p < 0.05.  173 
 174 
Results:  175 
Reduction of Ki67, Sox9, Ber-EP4, Bcl-2, cilium expressions on BCC after the treatment 176 
with Hh pathway inhibitors 177 
In all 23 pre-treatment biopsies, diagnosis of BCC was histologically confirmed in HE stained 178 
sections by a board certified dermatopathologist (RD). Twenty three patients  (10 male, 13 female; 179 
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46 - 90 years; mean 70 years) were all partial responders of Hh pathway inhibitor treatment. 180 
Further investigation was focused on 5   patients (Table 1) with paired biopsies taken before and 181 
after 4 weeks treatment with Hh pathway inhibitors, who consented to the biopsy for clinical 182 
research. All patients suffered from locally advanced BC without Gorlin's syndrome. Clinical 183 
presentation and histological diagnosis of these patients are summarized in Table 1. In all cases, 184 
comparison of HE stained sections from before and after 4 weeks of Hh pathway inhibitor 185 
treatment showed a tumor regression with a reduction of the tumor nest (Figure 1A). The 186 
morphology was altered with a more eosinophilic staining pattern and signs of cornification 187 
suggesting a transdifferentition into a squamous phenotype. In one case we observed the formation 188 
of cytic structures filled with keratin (Figure 1A).  189 
We examined the expression of tumor- or BCC-associated proteins by immunohistochemical 190 
staining. In all cases, we found dramatic reduction of the expression of the proliferation marker 191 
Ki-67, the stemness marker Sox9, the hair follicle-specific antigen Ber-EP4, and the anti-apoptotic 192 
molecule Bcl-2 on the tumor cells after 4 weeks treatment with Hh pathway inhibitors (Figure 1A, 193 
B). This was in one case associated with cyst formation.  194 
   The primary cilium has emerged as an important organelle that is required for Hh signaling (9). 195 
However, it is still unknown how cilia change on human BCCs during Hh pathway inhibitor 196 
treatment. Therefore, we next examined the expression of cilia that are identified by acetylated 197 
tubulin.  In all cases investigated, we found ciliated BCC cells by immunofluorescence. 198 
Intriguingly, the number of cilia-positive cells on BCC is significantly decreased after 4 weeks 199 
treatment compared to that before Hh pathway inhibitor treatment (Figure 2). We confirmed that 200 
there was no non-specific staining for cilia (Supplementary Figure S1A). 201 
Promotion of adaptive immune cell infiltration and up-regulation of MHC class I in BCCs 202 
following Hh inhibitor treatment  203 
We next analyzed the effect of Hh pathway inhibitor treatment on immune reactions in BCCs.  In 204 
pre-treatment biopsies, CD68+,CD4+ ,CD8+ and FoxP3+  cells were rare and solely located in the 205 
stroma. Immunohistological staining revealed an increase and invasion of CD8+ T cells into tumor 206 
cell nests (Figure 3A) with an upregulation of MHC Class I expression on tumor cell membranes 207 
(Figure 3B, Supplementary Figure S2). Interestingly, at week 4 an increase of peri- and 208 
intratumoral CD4+ T cells was detected in the tumor area (Figure 3C). In addition, the number of 209 
HLA-DR-Class II+ mononuclear cells was significantly increased in the intratumoral and 210 
peritumoral areas after 4 weeks of treatment (Figure 3D).  211 
   Moreover, the number of CD68+ macrophages was significantly increased in the intratumoral 212 
and peritumoral areas after 4 weeks of treatment (Figure 4A). BCC has been shown to be 213 
associated with regulatory T cells (Tregs) that could contribute to an immunosuppressive activity 214 
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against tumor-specific T cell responses (16). Therefore, we next analyzed the number of Foxp3+ 215 
Tregs. The number of Tregs was significantly increased in the intratumoral and peritumoral areas 216 
after 4 weeks of treatment (Figure 4B). Interestingly, the ratio CD8+/Foxp3+ was increased only in 217 
the intratumoral and but not in peritumoral areas (Fig. 4C). We confirmed that there was no non-218 
specific staining (Supplementary Figure S1B). 219 
 220 
Change of the cytokine and chemokine milieu after Hh pathway treatment 221 
It is likely that there is an immunological change after the treatment of Hh pathway inhibitors.  To 222 
address this issue, we performed qRT-PCR using an array that included 84 cytokines and 223 
chemokines. The results showed 6 genes to be differentially expressed after Hh pathway inhibitor 224 
treatment. Of these 6 genes, 5 were upregulated by at least 2-fold after the treatment and 1 was 225 
downregulated at least 2 fold after treatment (Figure 5). There was a significant increase of the 226 
expression levels of the chemokines and cytokines: chemokine (C-C motif) ligand (CCL)18, 227 
CCL21, chemokine (C-X-C motif) ligand (CXCL) 9, vascular endothelial growth factor a 228 
(VEGFA) and tumor necrosis factor ligand superfamily member 11 (TNFSF11, receptor activator 229 
of nuclear factor kappa-B ligand, RANKL). Furthermore, the qPCR results showed a consistent 230 
decrease during treatment of the expression levels of tumor necrosis factor receptor superfamily 231 
member 11B (TNFRSF11B, osteoprotegerin) (Figure 5). The expression level of interferon (IFN)-232 
γ increased 1.63-fold but this was not significant. 233 
 234 
 235 
Discussion 236 
This study reports on the histological alterations on the tumor cell population and the 237 
inflammatory tumor microenvironment of patients with BCCs as a result of Hh inhibitor 238 
treatment. The data provide evidence that the Hh pathway- induced tumor regression leads to a 239 
dramatic change in the microenvironment that is characterized with a disruption of immune 240 
privilege and the activation of the adaptive immune effector functions.  241 
   A previous study demonstrated that vismodegib showed a 30 and 60 % response rate for 242 
metastatic and locally advanced basal-cell carcinoma (5). However, most responses were partial 243 
responses. In addition, significant adverse events with negative impact on the quality of life 244 
including muscle spasms, alopecia, dysgeusia, weight loss, and fatigue were occurred in more than 245 
30% of patients. Therefore, improvement of the therapy using Hh pathway inhibitors is required. 246 
In this study, we demonstrated that Hh pathway inhibitors promoted adaptive immunity via 247 
upregulation of MHC class I and infiltrating immune cells into the tumor sites. A combination 248 
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therapy with immune modifiers has a possibility to improve the efficiency by shortening the 249 
treatment related drug exposure and achieving a complete remission rate. 250 
 We demonstrated substantial alterations in the immune- microenvironment with an intra- and 251 
peritumoral increase of CD4+ and cytotoxic CD8+ T cells and an up-regulation of MHC class I 252 
during tumor regression under treatment with Hh pathway inhibitors. In addition, reduction of 253 
primary cilia was observed after Hh pathway inhibitor treatment. Primary cilia have been 254 
implicated in Hh pathway signaling and ablation of cilia in SMO activated cells inhibits tumor 255 
growth (17). Before treatment, all BCC cells are ciliated, suggesting that they are responsive to Hh 256 
signalling. By inhibiting Hh signaling, the BCC cells lose their cilia and subsequently stop 257 
proliferating, as seen in the reduction of Ki-67 staining.  258 
   T cell activation requires both T cell receptor (TCR) and co-stimulatory molecule ligation by 259 
professional antigen-presenting cells (APC), and the outcome of the stimulatory signal is 260 
influenced by the microenvironment of the T cell and the APC. Hh signaling pathway reduced the 261 
strength of the TCR signal in mature peripheral T cells (18, 19). Additionally, the repression of the 262 
Hh signaling pathway in T cells increased T cell activation (20). This suggests that the Hh pathway 263 
inhibitor has direct effects on peripheral T cell and activates adaptive immune responses. The 264 
precise mechanism of the Hh inhibitor on immune modulation requires further investigation.   265 
   RT- PCR results showed that the expression levels of different chemo- and cytokines changed 266 
during treatment (Figure 5). Although these are limited in number, our data suggest that these 267 
changes in the immune environment may be crucial for tumor control and highlights the poorly 268 
understood interface between targeted therapy and immune responses. BCCs frequently express 269 
multiple cancer testis antigens but are also associated with relative absence of MHC class I 270 
molecules from tumor cells and it has been hypothesized that BCCs produce immunosuppressive 271 
factors such as IL-10 (2, 21) and therefore are resistant to adaptive immune response. This might 272 
explain the absence of infiltrating CD8+ cells in BCC.   We found that the chemokines CCL18, 273 
CCL21, CXCL9 were up-regulated during treatment with Hh pathway inhibitors. These 274 
chemokines are produced and secreted by innate immune cells such as macrophages and exert 275 
their effect mainly on the adaptive immune system. It is known that epithelial cells can produce 276 
CCL18, CCL21, and CXCL9 (22-24).  These chemokines are thought to have a critical role in 277 
tumor suppression. Interestingly, high CCL18 or CCL21 expression was reported as a favourable 278 
prognostic factor in patients with colorectal cancer (25, 26).  Additionally we found an 279 
upregulation of VEGFA during treatment, which may support granulation reactions with 280 
angiogenesis in regressive BCC lesions. 281 
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 Although the expression level of IFN-γ increased 1.63-fold, and was not significant in this study, 282 
our current findings provide an indirect indication for an IFN-γ primed micro- environment 283 
favoring immune response. It is known that IFN-γ up-regulates MHC class I antigen presentation 284 
by inducing gene expression signatures that are related to MHC class I antigen processing and 285 
presentation including activation of JAK/STAT1 signal transduction pathway (27). Furthermore, 286 
changes in cytokine profiles with up-regulation of CXCL9 (also known as Monokine induced by 287 
gamma interferon (MIG)), which has chemotactic activity on T cells induced by IFN-γ, supports 288 
this hypothesis.  A potential cross-talk between IFN-γ and the Hh pathway was recently described 289 
by Laner- Plamberger et. al (28). They demonstrated that suppressor of cytokine signaling 1 290 
(SOCS1) is a direct target of Hh/GLI signaling in human keratinocytes and medulloblastoma cells 291 
and a potent inhibitor of IFN-у -STAT1 signaling, which can induce cell cycle arrest, apoptosis 292 
and anti-tumor immunity. It was shown that the transcription factors GLI1 and GLI2 activated the 293 
SOCS1 promoter and STAT1 phosphorylation was reduced in cells with active Hh/GLI signaling 294 
(28). mRNA levels including IFN-γ depend on when the samples are collected (29, 30). A previous 295 
report showed that IFN-γ mRNA expression in the skin infiltrated IFN-γ producing T cells 296 
increased at the peak of 12 hours and diminished after 24 hours in skin allergic inflammation (30). 297 
In addition to the limited number of samples in this work, the biopsy time point may be too late to 298 
directly document the IFN-γ peak. 299 
 In vitro studies on bone tissue showed that Hh signaling indirectly induced osteoclast 300 
differentiation by upregulating osteoblast expression of parathyroid hormone-related protein 301 
(PTHrP), which promoted RANKL expression. (31) Mouse models on human bone tissue 302 
emphasized these results. RANKL was induced by activation of the Hh pathway and the 303 
expression of RANKL was inversely associated with that of HLA-G5, especially with Hh 304 
stimulation (32). Our analyses of cytokine profiles showed an up-regulation of RANKL during 305 
treatment with Hh inhibitors. RANKL is also expressed by Th cells and is thought to be involved 306 
in dendritic cell maturation as well as the regulation of T cell-dependent immune responses,  307 
    In conclusion, we demonstrated that Hh pathway inhibitor treatment induced tumor regression  308 
were accompanied by a recruitment of cytotoxic T cells into the tumor and reduction in the 309 
frequency of ciliated cells, which appeared to be required for Hh inhibitor efficacy. Therefore, we 310 
propose that these immune responses are crucial for long-term tumor control and hypothesize that 311 
a combination of Hh inhibitors with immune modifiers might be therapeutically beneficial.  312 
 313 
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 404 
 Table 1 Clinical presentation and Histology of the 5 patients with paired biopsies 405 
Patient Clinical presentation  Histology before 
treatment  
Histology after 4 weeks Tumor size (after 4 
weeks and 8 weeks) 
Best response after 
weeks of vismodegib 
treatment 
1 Locally advanced, 
facial, ulcerated, 
Solid BCC Regression of tumor with 
inflammatory infiltrate 
120×80mm, 120×80mm 
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150×80 mm 
measuring BCC  
CR after 16 weeks 
2 Locally advanced, 
thoracal, ulcerated, 
80×60 mm 
measuring BCC 
Solid BCC Regression of tumor with 
inflammatory infiltrate  
80×60 mm, 50×40 mm 
 
PR after 12 weeks 
3 Locally advanced, 
facial, ulcerated 
50×60 mm 
measuring BCC 
BCC with 
basosquamous 
differentiation 
Epithelial tumor rests 
infiltrated by 
inflammatory cells.  
 
40×40 mm, 40×35 mm 
 
PR after 16 weeks 
4 Multiple locally 
advanced, recurrent 
BCC, 10×12 mm 
with lower leg 
 
Superficial BCC Superficial tumor rests 
and inflammatory 
infiltrate 
 
10×12 mm, 10×10 mm 
 
PR after 12 weeks 
5 Multiple BCC, 
45×15 mm with 
upper arm 
Superficial BCC Regression of BCC with 
focal basosquamous 
differentiation, 
inflammatory infiltrate 
and cystic formation.  
 
45×15 mm, 45×10 mm 
 
MR after 12 weeks 
 CR: complete remission according protocol 406 
PR: partial remission according protocol 407 
MR: minor remission (not qualifying for PR, but clinical improvement) 408 
 409 
Figure legends: 410 
Figure 1: Histology and Immunohistochemical stainings of Ki67, Sox9, BerEP, and bcl2 411 
(A) HE staining and Ki67, Sox9, BerEP, and bcl2 by immunohistochemical staining of a 412 
representative pair of biopsies with different high power fields before and after 4 weeks treatment.  413 
Scale bar; 100 µm (B) Ki67, BerEP, Bcl2, and Sox9 expression on tumor cells was quantified by 414 
investigation of 4 ×40 HPF representative of different patients and different high power fields per 415 
sample and evaluated as grade 1 (< 10% of cells or none staining for Sox9), grade 2 (10- 30% of 416 
cells or weak staining for Sox9) and grade 3 (>30% of cells or strong staining for Sox9). 417 
 418 
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Figure 2:  Expression of cilia and SOX9                                                                                                            419 
(A) Cilia, and Sox9 by immunohistochemical staining of a representative biopsy pair before and 420 
after 4 weeks treatment. (B) 3 x 100 HPF representative areas per sample were counted in BCC 421 
biopsies from patients before and after 4 week treatment with Hh inhibitors (n=4). *, p < 0.05 422 
Figure 3: CD4, CD8, HLA-DR-class II, and MHC class I expression.  423 
MHC class I expression on tumor cells was quantified by investigation of 4 ×40 HPF of a 424 
representative biopsy pair and evaluated as grade 1 (< 10% of cells), grade 2 (10- 30% of cells) 425 
and grade 3 (>30% of cells). Quantification of CD4, CD8, HLA-DR-class II + cells in intratumoral 426 
and peritumoral regions was done by counting cells in high-power fields (HPF) of ×40 427 
magnification. For each section, 4 ×40 HPF representative areas per sample were counted from 428 
patients before and after 4 week treatment with Hh inhibitors. *, p < 0.05 429 
Figure 4: Immunohistochemical stainings of CD68, and Foxp3.  430 
(A, B) For CD68 and Foxp3 staining, 4 x 40 HPF of a representative biopsy pair are shown and 5 431 
pairs were counted in BCC biopsies from patients before and after 4 week treatment with Hh 432 
inhibitors (n=5). *, p < 0.05 (C) The ratio CD8+/Foxp3+ was increased only in the intratumoral 433 
and but not in peritumoral areas. 434 
 435 
Figure 5:  Changes in cytokine profile  436 
PCR array of paired biopsies (n=3) before and after 4 weeks of treatment with Hh inhibitors 437 
showed an increase of the expression levels of different chemokines and cytokines: CCL18, 438 
CCL21, CXCL 9, VEGFA and TNFSF11 (RANKL), and consistent decrease during treatment of 439 
the expression levels of TNFSF11 (RANKL) receptor TNFRSF11B. *, p < 0.05 440 
 441 
 442 
 443 
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